Various types of cancer enhance NRF2 function in multiple ways, including genetic mutations in KEAP1 that disrupt their interaction and are found in 17% of lung adenocarcinoma (LUAD) cases [6]. Here, KEAP1 is linked to lung adenocarcinoma.